FASTING LEVELS OF GROWTH HORMONE AS PREDICTIVE MARKER OF CARDIOVASCULAR RISK Russian patent published in 2019 - IPC G01N33/74 G01N33/53 

FIELD: medicine.

SUBSTANCE: invention relates to a method for predicting cardiovascular risk over a period of 10 years in an individual, comprising determining the level of growth hormone (hGH) or its fasting isoforms in blood, plasma or serum taken from said individual, where the growth hormone isoform (hGH) is selected from the group including isoform 1 hGH, isoform 2, isoform 3 and isoform hGH 4 (SEQ ID NO: 1–4), and the correlation between the indicated level of growth hormone (hGH) or its fasting isoforms and cardiovascular risk is established, however, a level that is greater than the threshold value is a prognostic criterion for increased risk. Cardiovascular risk is defined as an adverse event, the risk of the said adverse event is predicted for a period of time within 10 years and the risk is defined as an adverse event, selected from the group including stroke, CVD (cardiovascular disease) mortality and coronary artery disease (CAD), where the latter includes fatal or nonfatal myocardial infarction, death from ischemic heart disease, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Also the invention relates to the use of ultrasensitive hGH analysis in this method.

EFFECT: fasting growth hormone levels have been suggested as a predictive marker of cardiovascular risk.

22 cl, 5 tbl, 2 ex, 2 dwg